145 related articles for article (PubMed ID: 20075048)
1. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly.
Domínguez A; Izquierdo C; Salleras L; Ruiz L; Sousa D; Bayas JM; Nebot M; Varona W; Celorrio JM; Carratalà J;
Eur Respir J; 2010 Sep; 36(3):608-14. PubMed ID: 20075048
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.
Vila-Corcoles A; Ochoa-Gondar O; Rodriguez-Blanco T; Gutierrez-Perez A; Vila-Rovira A;
Hum Vaccin Immunother; 2012 May; 8(5):639-44. PubMed ID: 22634442
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.
Vila-Corcoles A; Ochoa-Gondar O; Guzmán JA; Rodriguez-Blanco T; Salsench E; Fuentes CM;
BMC Infect Dis; 2010 Mar; 10():73. PubMed ID: 20298596
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of 23-valent pneumococcal polysaccharide vaccine and seasonal influenza vaccine for pneumonia among the elderly - Selection of controls in a case-control study.
Kondo K; Suzuki K; Washio M; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2017 Aug; 35(36):4806-4810. PubMed ID: 28818473
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study.
Wiemken TL; Carrico RM; Klein SL; Jonsson CB; Peyrani P; Kelley RR; Aliberti S; Blasi F; Fernandez-Gonzalez R; Lopardo G; Ramirez JA;
Vaccine; 2014 Apr; 32(19):2198-203. PubMed ID: 24613522
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
Domínguez A; Ciruela P; García-García JJ; Moraga F; de Sevilla MF; Selva L; Coll F; Muñoz-Almagro C; Planes AM; Codina G; Jordán I; Esteva C; Hernández S; Soldevila N; Cardeñosa N; Batalla J; Salleras L
Vaccine; 2011 Nov; 29(48):9020-5. PubMed ID: 21939724
[TBL] [Abstract][Full Text] [Related]
12. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M; Feldman BS; Brufman I; Cohen-Stavi CJ; Hoshen M; Balicer RD
Clin Infect Dis; 2015 May; 60(10):1472-80. PubMed ID: 25669354
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
15. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
Johnstone J; Marrie TJ; Eurich DT; Majumdar SR
Arch Intern Med; 2007 Oct; 167(18):1938-43. PubMed ID: 17923592
[TBL] [Abstract][Full Text] [Related]
16. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain.
Domínguez À; Soldevila N; Toledo D; Torner N; Force L; Pérez MJ; Martín V; Rodríguez-Rojas L; Astray J; Egurrola M; Sanz F; Castilla J;
PLoS One; 2017; 12(2):e0171943. PubMed ID: 28187206
[TBL] [Abstract][Full Text] [Related]
19. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis.
Hedlund J
Scand J Infect Dis Suppl; 1995; 97():1-60. PubMed ID: 8584866
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.
Peñaranda M; Falco V; Payeras A; Jordano Q; Curran A; Pareja A; Samperiz G; Dalmau D; Ribera E; Riera M
Clin Infect Dis; 2007 Oct; 45(7):e82-7. PubMed ID: 17806042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
